GUANGJI PHARMA.(SZ:000952)2023-05-25 14:14Group 1: Company Development Strategy - The company will adhere to a "raw materials + formulations + health" deep development strategy to promote high-quality development, focusing on internationalization, precision, and greenness [2] - The strategy includes expanding product lines in three key areas: pharmaceutical raw materials and formulations, high-value nutritional additives, and bio-based materials [2] - The company aims to strengthen investments in synthetic biology and leverage its established fermentation technology to enhance collaboration with research institutions [2] Group 2: Technological Innovation and Collaboration - The company plans to utilize its biotechnology research institute to explore and establish a technology innovation platform, with increasing R&D investment in recent years [2] - Collaboration with national and local entities is expected to enhance sales capabilities and increase the proportion of pharmaceutical business [2] - The company is focusing on developing traditional Chinese medicine health products in partnership with local universities and research institutions [4] Group 3: Production and Market Adaptability - The main tasks for the Jining company this year include resuming production and sales while improving process technology [3] - The Jining company's product range includes corn starch, gluconic acid series, lactic acid and its salts, which are expected to enhance market competitiveness and reduce operational risks [4] - The company aims to smooth out profit fluctuations and improve cash flow through a diversified product portfolio [4] Group 4: Advantages of Synthetic Biology Collaboration - The company has a comparative advantage in fermentation technology and aims to collaborate with synthetic biology firms to lower production costs and enhance product quality [5] - The application of synthetic biology is anticipated to revolutionize production methods in pharmaceuticals, food, and materials [5]